Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

NCT04746131 · clinicaltrials.gov ↗
PHASE1
Phase
SUSPENDED
Status
90
Enrollment
OTHER
Sponsor class

Stopped Due to the product development strategy change, without any safety concerns, we (the sponsor of the trial) have decided to request to place the IND (#151570) on inactive status.

Conditions

Interventions

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Collaborators